newsfilter
← Latest News
Earnings Call Transcripts·

NOVAVAX, INC. - JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - NOVAVAX INC

All right, welcome everyone to Jefferies' 2026 Global Healthcare Conference in London. And my name is Roger Song, Senior Analyst, cover Smica Biotech in the U.S. It is my great pleasure to have the fireside chat with Noah Vax. We have the full crew here, John Jacobs, CEO, Jim Kelly, CFO, and then Elaine O'Hare, Chief strategy officer, and then we have a Bob Walker, head of R&D. Yeah. Welcome, gentlemen, and then lady. And then maybe, John, why not you start with the, you know, particularly for the investors who are relatively new to Novavax, which they should not be. But, you know, since you joined Novavox two years ago, launched a new strategy as a new CEO, and then what you have been achieved, and dann what's the, no, the future look like in why you're excited roger it's been a remarkable transformation of the company that we're very excited about and we've we've changed the company from a vaccine company focused on marketing it's one asset at the time which was a vaccine for covet and taking this technology platform which is the reason i came here phenomenal platform and looking to share that more with the world throughout licensure and partnering so we converted the company a fully integrated global company selling one product in a pandemic to a company that out licensed our tech with the goal of building value and revenue value and revenue through partnering i'm not sure if we lost audio here guys but we should be okay look we believe our technology can underpin a wide variety of vaccines in viral and bacterial targets and infectious disease where we started and where we have proof of concept and potentially in oncology, where we're in the stages of early exploration on how our technology might fit into that emerging ecosystem with vaccines. And when we look back just on 2026, we're very proud of our accomplishments as a team. Year two of this new strategy that we launched, we've had some significant milestones and achievements, including bringing Pfizer in as a new partner with a half billion dollar headline and potential milestones across two fields and a $30 million up front for Pfizer to engage with and explore our technology and hopefully bring forward more than one asset to help people in the future as a great partner. We just earned in the last month or so $125 million milestone from our ongoing partnership with Sanofi for their clinical initiation of a combination COVID flu vaccine, with their world-leading flu vaccine, and our differentiated COVID vaccine, non-mRNA protein-based. That trial started in Europe. We earned that milestone. They also indicated their intention to start a combination vaccine trial in the U.S. market. And as a reminder for our audience, should they achieve a first sale of a combination vaccin with our COVID vaccine in the U.S., we would be eligible to earn a $225 million milestone and ongoing royalties for potentially decades after the launch of these products. We also, through the course of 2026, signed up additional initial partners through MTAs, or Material Transfer Agreements, where these companies get to explore our technology in their own laboratories with the hopes that those, too, may turn into, eventually, license agreements for the company, similar to those of Pfizer and or Sanofi. In addition, Roger, despite reducing our expenses between 80% and 90% over the last few years, we've maintained our capabilities to drive R&D. We make select investments in our R&d, and we use that to help fuel this partnering model. So through the year, we've advanced our experiments with existing commercialized vaccines by adding our matrix to many of those methodically generating data that Elaine and her team can then go into potential partners with existing partners with and we can show them what their assets or their portfolio targets look like when they add our technology to hopefully foster more partnerships and last but not least we're advancing our own C difficile vaccine with intention of being in the clinic as early as 2027 and again with the primary intention about licensing that and generating more partnerships so that's 26 we can talk later about what's ahead head on Catalyst but very excited about where we are two years into this strategy right now. Excellent. Okay this is a great overview and then let's talk you know each session in order you know the Novavax is no longer one product company and then you have platform, you have a lot of partnership. COVID will still be the near-term value driver. Let's maybe just zoom in a little bit on that end. So take a step back how we've been I think we've been through kind of COVID but still it still kind of persists yes how we think about the global COVID market and then particularly in the context of the potential combination with the flu and COVID so maybe maybe important question Roger Jim you want to take that well certainly you know I think one of your your initial observations there that we are a company with multiple layers of Value creation from commercial products live in the market and the facts of it with Sanofi to now a phase three combination kick influenza product being launched by Sanofи and then a full pipeline full of catalysts. You know, there's a lot here in the coming quarters and years to drive value creation. And then in particular, when we look at the COVID and the flu marketplace, I think people might remember last year was a choppy market. this year it looks flat to up it looks like we've seen great stabilization and I'm referencing U.S. market statistics at this time but when we think about the COVID and the flu markets and you add their global revenues together you have over a 10 billion dollar marketplace and I am purposely describing both because what the market is demanding is better compliance and combination therapy, you know, combination vaccines. And Sanofi, with their phase three, intends to be an early entrant, right, an early mover in that marketplace, which is incredibly exciting when you consider they're taking Arnavaxavit and combining it with one, perhaps two, of their market-leading enhanced flu products, right? So think about high-dose Fluzone and FluBlock. They have almost two-thirds market share in the enhanced flu, which is the exact use case and vaccination case for Novavaxavid. So this is a great partnership. What they have the ability to do in the coming years, continue to methodically build Novavavid en route to combining it with that market-leading flu franchise. And that's what we're excited about. All right, to the point of the market sizing. You know, what we're seeing with COVID in particular, the market last year was $6.8 billion globally, of which $2.9 billion was in the U.S. and then the remaining ex-U.S., year-to-date, season-to date. In the U。S., it's flattish. It's like single-digit declines, but recent weeks exceed prior year. So we expect a firming of the U.S. market for COVID on the ex-U.S.-basis. You know, we're hitting the end of some of those legacy APAs, and in Europe in particular, the Pfizer agreement the last year is this year. So I think we're going to get a very good read on the size of the European market this year, absent that agreement in Europe, and then next year, I think, a great run rate. either way I think you got a four or five billion dollar stable market so that that's what the marketplace looks like today awesome and then this year is the first year your partner Sanofi is having a full year commercialization I know it is an early year for them and then that what have you observed from your partner and then what have they done and then you know any performance you can you know in the context of it that you can discuss Elaine you want to take that one? Yeah, thanks, John. We, at the macro level, we're really very excited about the commitment that Sanofi has shown since we entered into our collaborative license agreement back in 2024. And every step of the way, we really have had a very profound partnership underscored by our announcement early November that they were entering into their phase three study in Europe. That's an immunogenicity study for the combination influenza and COVID program. in people over 60, and then also their recent statement that they would be initiating a phase three study in the U.S. in 2027. So both of those events are extremely important to us. Obviously, we have our milestone that's associated with that, as both John and Jim mentioned, of $225 million for the first sale when they are commercialized in the US. So very exciting times, and we've literally been working hand-in-hand, hip-by-hip over the last couple of years to make sure that the products are successful and come to market, and then, of course, that we achieve our milestones as well. Specific to this season, again, a nice year. We're happy with what we see, a good share so far. Sanofi has initiated their contracting late last year, which is typical, and are in all major retailers in the U.S. in 2026 for the season and have run fairly substantial pilots across the retailers. And so what we see is Nuvaxavit is quite promotionally sensitive. So in the pilots that they ran, we saw reordering for NuvaxaVit product and in specific areas a share that was quite significant as well where NuvaXavit was being preferentially offered in those retail settings. So again, with the investment of direct-to-consumer advertising, best-in-class Salesforce, best in class national accounts team, really a nice year this year. And obviously, together, our goal is to make sure that we drive awareness of Nuvax of it in both the US and ex-US markets. We've seen some add-ons as well from an ex-U.S. perspective as they start to expand globally for NuvaX of it as well. All with the, as I said, leading up to the macro level of getting to that point where when you're launching your combination influenza and kick program, you can be very successful. So very happy with what we see and delighted with the partnership and happy to continue over the next several years. Yeah, we'll look to see them work to build a material share over time, Roger. It's going to be a methodical approach. They have a foothold now in the U.S. to start, and we expect to see then build upon that year after year. In summary, Sanofi's leaning in, not away. They're making the investments in DTC, in advertising, in building awareness, in piloting different types of approaches with U.S. retail, in approaching tenders to try to win those in the rest of the world outside of the U.K. because it's a global marketplace, and investing in the combination, COVID flu program and paying us those milestones, spending on those clinical trials. And that's one of the elements of our strategy, San Ofi or with Pfizer or with other intended future partners that we have, that we leverage their expertise, their resources, and their scale to help us advance our technology more quickly and have a vision where we have multiple vaccines across multiple portfolios with multiple partners making a huge impact and a legacy on global health. That's the vision. Got it. Okay, great. And then one specific question related to U.S. Phase 3. Would that be an immunogenicity-driven trial or it's more of a field efficacy trial, number one? Number two is how much those learning experience marketing the COVID alone and then when the kick or the COVID flu vaccine coming to the market and then they can leverage that learning and then to expand, you know, rapidly to get that market share. Two-part question. Bob, you want to take the first part on the potential study design in the U.S. and Elaine can cover the commercial piece there. Yeah, sure. We just reiterate how excited we are that Sanofi has publicly stated, has actually initiated their European phase three trial and publicly stated their intent to initiate a phase three trail in the U.S. next year. Now, in terms of the design of the Phase III study in the U.S., it's worth reminding folks that we do not have access to Santa Fe's plans, activities, timelines related to KIC other than what they publicly state or what they may confirm to us. So we can't really comment on the specific design. But we're excited, and we're really looking forward to it. And what we can say, Bob, is what they've said publicly, that they have intention to start a combination clinical trial in the U.S. market next year. So those are their public comments, so we can repeat that for the audience here who might not have heard them say that, but that's their intention. And it would be logical to assume they have an idea of regulatory pathway or they wouldn't be saying that in their public commentary. So we're exciting about their commitment, already starting the trial and running it in Europe, and their stated commitment to the U.S. market next year. Okay, good. And then when the kick is coming to the market, how much learning you can leverage from the flu, from the COVID marketing, and then they can rapidly kind of get a market share in the U S and X? Yeah, no, it's a great question. And they, they have stated that they see room for three to four products in their armamentarium to address respiratory illness. So standalone flu, standalone COVID, and then potentially two combination influenza and COVID programs or products one with flu block as Jim mentioned earlier and one with flus on high dose right so there is a space for all of those products in the marketplace I think what's really interesting is the driving of the trend obviously towards a combination product and so to answer your question Roger exactly they have profound experience that they're number one flu vaccine company globally right so and being able to address a need for a potential non-mRNA flu and COVID vaccine I think is incredibly important both in the U.S. and ex-U.S., so there's a nice opportunity there for a differentiated portfolio of products, which is exactly what Sanofi intended to do from a strategic perspective. Okay, very good. I think we spent a fair amount of time on the COVID flu because that is the near-term kind of value driver but we it's not lost on us and when you are shifting more on the partnership strategy and also you're building your own you know internal pipeline so on the partnership so you already sign a lot of the MTA and then some of the convert including fighter that's very encouraging to see and then what's next right then and then how you gonna seems you are expanding from infectious disease to the oncology what drove that and then What's the status of that because we haven't seen anything coming from the cancer side yet? You know, I'll let Elaine put some more context around these things. On the partnering side, it's important that we have four existing partners right now. We have Takeda, we have Sanofi, we Pfizer, we CIRM, Institute of India. And what we see and what we have seen to date are that as our partners get exposed more and more to our technology, the interest continues to be strong and or even grow. Right? So you've seen Sanofi continue to lean in and invest to move forward with the other pieces of that contractual agreement that was signed just over two years ago now, right? We've seen remarkable interest in our tech from existing as well as potential new partners. So Elaine, you might want to comment on our process that we take regarding generation of data and conversations with potential partnerships and then next steps potentially from there and how that might evolve. Yeah, absolutely. focus in a little bit on the question you asked as it relates to oncology. So obviously MatrixM is technically part of a marketed product. So it's got a substantial safety and efficacy database associated with it. So, it's a trusted adjuvant. Several years ago, we started to think about the utility of MatrixM in oncology as a way to potentially unlock value in the oncologic setting, create more durable, long-lasting CD8 T-cell responses. Cellular response is really what everybody's interested in when it comes to oncology vaccines, obviously. And so we initiated some experimentation internally and saw very positive data, again, preclinical data. We also had a relationship with an external company, generated some positive data there. And the combination of some of these things then also led us to an MTA with an oncology company, and so they're in the midst of their experimentation work pre-clinically as well. So very excited about that opportunity and what lies ahead. In general, when we look at MTAs, that's a process whereby we engage with a company and they do experimentation work with our MatrixM platform, again, sort of hinting back at the safety database, efficacy, et cetera. And so it's an adjuvant that can work, obviously, very well in infectious disease. And we also have MTAs with other companies in infectious diseases, and now we're systematically exploring the oncology opportunity as well. So very interested to see what's going to come out of our experimentation set both internally as well as externally throughout 2027. MR. And, Roger, it's obviously our intent that as many of these interactions as possible would turn into license agreements in the future. obviously not everything that they try or we try will work not every MTA will turn into a deal but what we really like about our strategy is we continue to put multiple opportunities on the table to potentially succeed and in biotech you just need a few of those things to succeed over time to really start to build hopefully meaningful value it's our intention to have have future partners emerge through these efforts and we'll keep working on it every day Okay. Yeah, multiple shots on goal. That's the goal. Yes. And then, you know, you did sign a partnership with the fighter coming out of the MTA. Right. So that's another example of that, right? And then just forward-looking, right, so it's not like you have official guidance. Should we expect to see something coming from 2027? Or the timeline-wise, because you already have, I forgot, they have how many MTA already ongoing. it's been a while right how long usually gonna take you to have a very tangible partnership nothing everything gonna convert to the partnership just again Elaine can provide some additional color but we won't provide forecasts or estimates on timing there it's a good question everybody wants to know we'll always know a lot more than we can share with you on these types of things but because we don't control the final outcome on some of those if it's a partner on their side you know we don t want to predict timing but we what we can say is we've seen remarkable interest in our technology and that's very strong and even getting stronger as we move through the year the last couple of years of our strategy so very excited about what we see anything to add Elaine on that no I think we know we're really looking forward to 2027 I think in terms of some of these some of the engagements and and what we're delighted to see maybe to answer your question is for the part for our existing partners we're delighted to see their interest in the matrix m platform um typically we're seeing an even deeper interest so so first mta potentially generating more and uh with some of our new partners again we're still uh you know looking forward to seeing what's going to come out in 2027 but uh very good significant interest in matrix m all around okay so so one of many catalyst to look for in 2027 and beyond would be additional partners potentially coming on board for Novavax as well as potentially existing partners deepening their relationship leaning in even further and continuing to invest in our technology and advance these relationships I hope you just say 2027 but you did say and beyond but you know I think you know people know as a company you know have that partnership strategy you want to see those partnership getting no broader continuously over time not just in the next four quarters right so again we won't promise a specific timing on any any partnership that comes and we will be limited in what we can say about certain partnerships we have to protect the intellectual property and the integrity of these agreements with our partners and so unlike some other companies where they can show you a clinical catalyst that comes in everyone sees it and can model it we have guard the confidentiality of these discussions and relationships as part of our capital in the new strategy with these partners so it's a little difficult sometimes for you guys to get line of sight on what may come but we're intending to do more and we're excited about what we're seeing okay good CDF that's your internal pipeline and then you did generate very interesting data so far and then what's next up for the clinical development and then is that also up for partnership if you you know what stage you will start to think about the partnership. Go ahead, Bob. Thanks, Archer. So we're also very excited about this particular candidate. We're excited because C. diff is a field that has a tremendous medical need and large burden of illness. There's no current vaccine available, and we believe our candidate is differentiated from the most advanced candidate in clinical development currently. We have a pentavalent that's targeting both toxin and non-toxin antigens. We have matrix M in addition to increase the immunogenicity and induce mucosal immunity, mucasal IgA in the gut, which is what most experts in the field agree is the immune marker that probably is most important. and the the vaccine is designed intentionally to cover more than 90 percent of circulating strains of c diff they use the term ribotypes circulating strains of C diff so for all those reasons we believe that we have a differentiated product we're very happy with the preclinical data that you alluded to in terms of you know the consistency and the activity that we see and in terms of where we are in next steps so we have initiated the pre-ind process with the fda and so we are fully engaged and interacting with them we've started gmp manufacturing a product in anticipation of starting a clinical trial perhaps as early as 2027 and And in terms of our ultimate goal here, our intent is to license a C. diff vaccine. And that is what we believe will actually create the most value for this particular vaccine. But, you know, we also have to wait and see as the data comes in. as we generate data, you know, we'll continually evaluate what's the best path forward for the company. Got it. And then just a quick follow-up, at what stage you will start to consider the partnership? It will be earlier or you will keep it a bit longer or it's data dependent? You want to take that one away? Yeah, I mean, it's a great question. I think we are obviously going to engage in discussions with partners as we start to see the data and what it looks like. So that's path one, but I also think we're interested in a potential path two if we decide that we want to retain our rights and keep the product. I think that's something that we would also consider as well. It's about optimizing the value, Roger. We'll see what the data tells us, and from there we'll see what's the best way to optimize value for our shareholders. Excellent. Okay, maybe just last minute. If, Jane, you can comment on the financial and then how all the, you know, strategy we describe and it's supported by the financial strength. And if you can give us a comment, that would be great. Well, certainly. And, you Know, I'd also love to give John a chance to speak to some of those critical catalysts next year as well. So we'll tag team on it, Jim. Absolutely. You know, one of the things we've done to create the environment to unlock a lot of value is financial stability. And over the past four years, you now, John and this team really leading a transformation of this company from a commercial company to now an R&D technology company with all these great partners you're hearing about. And our intent is tied to many important financial objectives, including, you know, let's make sure you have at least two years of cash at any time. You heard most recently, we've got at least three years. Hey, pay off those legacy APA liabilities by the first quarter of 2029. Non-GAAP profitability as early as 2029, And let's get that lean and agile model by 2028, 150 to 200 million. And so what you're hearing is that financial discipline intersecting with all the innovation, right, that John, Elaine, Bob have described. Awesome. Thank you, Jim. And, Roger, just to close out, you know, you asked about 27. If you look at near-term catalysts and what to expect in 27 and beyond from the company, Everyone should look to see when we announce new partnerships potentially. And equally important would be expanding existing partnerships, them leaning in. Pfizer selecting a second field, perhaps. They've already selected their first. Novavax earning some initial milestones potentially in the future from Pfizer as they advance programs, assuming success there. right look for us to generate data with existing vaccines that are commercialized with matrix m to share some of that data selectively to finish our first wave of pre-clinical experiments in oncology collect all of the data that elaine alluded to and that we're working on and to share Some of that selectively in the coming quarters as we learn more about where matrix may be able to play a role in that emerging ecosystem for vaccines look for us to continue to reduce our costs. And if you take a look at just near-term catalysts with our partner Sanofi alone, they're running that European trial now. Look for them to wrap that up and share the data and to make a file and for potential approval in Europe. To start that trial in the U.S. to get the data readouts there, potentially file with a potential launch in the US and a milestone for us. So we like to say 27 and beyond because all of these things are working in parallel. There's plenty of near- term catalysts to get excited about for Novavax, some of which we can't share with you too far in advance, or when those things happen in a material way, we intend to communicate them accordingly. Lots ahead. We've seen the future. We really like what we're building and where we're headed. Okay, excellent. Thank you.

Company
NOVAVAX INC
Keywords
NOVAVAX INC